AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8169104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection alone
Number of subjects: 175
Study 8169104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 175
Study 3253222 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbolevure
Number of subjects: 32
Study 3253222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 5046478 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 5046478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 5046478 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study 30160436 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elastic tape (experimental group)
Number of subjects: 28
Study 30160436 — intervention group
Group type: COMPARATOR
Intervention: Sham tape (control group)
Number of subjects: 28
Study 28993451 — intervention group
Group type: COMPARATOR
Intervention: Typical American diet (control)
Number of subjects: 412
Study 28993451 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 412
Study 28993451 — intervention group
Group type: COMPARATOR
Intervention: DASH diet vs control
Number of subjects: 412
Study 26875275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandiwich combined with artificial bone of tricalcium phosphate (trial group)
Number of subjects: 85
Study 26875275 — intervention group
Group type: COMPARATOR
Intervention: Sandiwich (control group)
Number of subjects: 85
Study 22795904 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 137
Study 22795904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 21628102 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB)
Number of subjects: 4
Study 21628102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical decompression
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical field stimulation
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking Nogo and Rho
Number of subjects: 0
Study 18980474 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of various cellular substrates
Number of subjects: 0
Study 17138713 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle bevel oriented away from the mandibular ramus
Number of subjects: 51
Study 17138713 — intervention group
Group type: COMPARATOR
Intervention: Needle bevel oriented toward the mandibular ramus
Number of subjects: 51
Study 12713066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine monotherapy
Number of subjects: 0
Study 12713066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine + Didanosine
Number of subjects: 0
Study 12713066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine + Zalcitabine
Number of subjects: 0
Study 12713066 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual nucleoside combinations
Number of subjects: 0
Study 12713066 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 0
Study 11103655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant adolescents
Number of subjects: 156
Study 11103655 — intervention group
Group type: COMPARATOR
Intervention: Pregnant adults
Number of subjects: 156
Study 9373762 — intervention group
Group type: EXPERIMENTAL
Intervention: linotroban
Number of subjects: 25
Study 9373762 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 1392111 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lithium succinate ointment (LSO)
Number of subjects: 30
Study 1392111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 4002806 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg M/day
Number of subjects: 21
Study 4002806 — intervention group
Group type: COMPARATOR
Intervention: 20 mg M/day
Number of subjects: 21
Study 31607561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cost patients with NIIEDs
Number of subjects: 14879
Study 29067867 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 10
Study 29067867 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 10
Study 27153158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of 9 µg of hemagglutinin (HA) per strain
Number of subjects: 149
Study 27153158 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 15 µg of HA per strain
Number of subjects: 149
Study 27153158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection
Number of subjects: 149
Study 27153158 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection
Number of subjects: 149
Study 24461315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (1500 mg daily)
Number of subjects: 50
Study 24461315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 capsules daily)
Number of subjects: 50
Study 22260857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF) (20% fat)
Number of subjects: 17
Study 22260857 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat high-omega-3 diet (LFn3) (23% fat with 3% as α-linolenic acid, eicosapentaenoic acid, and docosahexaenoic acid [DHA])
Number of subjects: 17
Study 22260857 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (HF) (40% fat)
Number of subjects: 17
Study 21049063 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day of paromomycin for 21 days
Number of subjects: 42
Study 21049063 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day of paromomycin for 28 days
Number of subjects: 42
Study 17984140 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg on the first day followed by 50 mg/kg/day for three days
Number of subjects: 27
Study 17984140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 27
Study 15793648 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy
Number of subjects: 88
Study 15793648 — intervention group
Group type: COMPARATOR
Intervention: Harmonic Scalpel hemorrhoidectomy
Number of subjects: 88
Study 11958351 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound cue AT followed by an outcome (AT+)
Number of subjects: 0
Study 11958351 — intervention group
Group type: COMPARATOR
Intervention: A alone paired with the outcome (A+)
Number of subjects: 0
Study 10606360 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg BID)
Number of subjects: 14
Study 10606360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8961043 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (not specified dosage or duration)
Number of subjects: 137
Study 1761079 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl 5, 10, 20 mg
Number of subjects: 30
Study 1761079 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltoprazine HCl 30 mg
Number of subjects: 30
Study 7017886 — intervention group
Group type: COMPARATOR
Intervention: Brain cortex phospholipids (BC-PL)
Number of subjects: 0
Study 31980871 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem gel 2%
Number of subjects: 55
Study 31980871 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorag® Emulgel
Number of subjects: 55
Study 30922355 — intervention group
Group type: EXPERIMENTAL
Intervention: Binafuxi granules (high-dose group)
Number of subjects: 240
Study 30922355 — intervention group
Group type: EXPERIMENTAL
Intervention: Binafuxi granules (low-dose group)
Number of subjects: 240
Study 30922355 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 240
Study 27783968 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced diuresis with matched controlled hydration (FMH)
Number of subjects: 150
Study 27783968 — intervention group
Group type: COMPARATOR
Intervention: Matched historical control cohort
Number of subjects: 150
Study 27601545 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy and 6 months of ADT
Number of subjects: 206
Study 27601545 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 206
Study 24868564 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront‐guided (WFG) PRK
Number of subjects: 71
Study 24868564 — intervention group
Group type: COMPARATOR
Intervention: Wavefront‐optimized (WFO) PRK
Number of subjects: 71
Study 24868564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 21685377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediated decision support related to prostate cancer screening
Number of subjects: 146
Study 19151384 — intervention group
Group type: EXPERIMENTAL
Intervention: Real therapy
Number of subjects: 221
Study 19151384 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 221
Study 17474541 — intervention group
Group type: EXPERIMENTAL
Intervention: Test syrup containing 15 mg dextromethorphan hydrobromide, 7.5 mg doxylamine succinate, 600 mg paracetamol, and 8 mg ephedrine sulfate (Group T)
Number of subjects: 432
Study 17474541 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (Group P)
Number of subjects: 432
Study 17474541 — intervention group
Group type: EXPERIMENTAL
Intervention: Test syrup (Group T)
Number of subjects: 432
Study 15465207 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 1143
Study 15465207 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 1143
Study 12195835 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4, 5, 9, or 18 micrograms b.i.d. via Turbuhaler)
Number of subjects: 34
Study 12195835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms t.i.d. via pMDI with spacer)
Number of subjects: 34
Study 12195835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9810788 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared tympanic membrane thermometry (LighTouch LTX Pedi-Q thermometer)
Number of subjects: 313
Study 9810788 — intervention group
Group type: COMPARATOR
Intervention: Axillary temperature measurement (mercury-in-glass thermometers)
Number of subjects: 313
Study 8577941 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) at 11.4 pmol/kg/min
Number of subjects: 36
Study 8577941 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) at 17.1 pmol/kg/min
Number of subjects: 36
Study 8577941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiodilatin/atrial natriuretic peptide (CDD)
Number of subjects: 36
Study 8577941 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (SALB)
Number of subjects: 36
Study 2229860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary-team approach to patient care
Number of subjects: 436
Study 348553 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk B (12.5 g of lactose)
Number of subjects: 150
Study 348553 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk C (37.5 g of lactose)
Number of subjects: 150
Study 348553 — intervention group
Group type: COMPARATOR
Intervention: Milk A (no lactose)
Number of subjects: 150
Study 30791510 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety signs depicting critical slopes in degrees
Number of subjects: 18
Study 30791510 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety signs depicting critical slopes as percent values
Number of subjects: 18
Study 30791510 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous involvement in machinery-related incidents
Number of subjects: 18
Study 27902988 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell and taste of milk before each feed
Number of subjects: 51
Study 27902988 — intervention group
Group type: COMPARATOR
Intervention: No exposure to the smell and taste of milk (control)
Number of subjects: 51
Study 26115809 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular management
Number of subjects: 37
Study 26115809 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 37
Study 23382300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense combined dietary-behavioral-physical activity intervention
Number of subjects: 22
Study 23382300 — intervention group
Group type: COMPARATOR
Intervention: Control group (age, gender, and obesity matched)
Number of subjects: 22
Study 21937521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 22
Study 21937521 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study 21937521 — intervention group
Group type: COMPARATOR
Intervention: Hyperthermia and Sham treatment
Number of subjects: 22
Study 19657277 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dk soft lens wear
Number of subjects: 10
Study 19657277 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dk rigid gas-permeable lens wear
Number of subjects: 10
Study 19657277 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye rubbing
Number of subjects: 10
Study 19657277 — intervention group
Group type: COMPARATOR
Intervention: Control (left eye)
Number of subjects: 10
Study 19657277 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral epithelium
Number of subjects: 10
Study 17466110 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy
Number of subjects: 301
Study 17466110 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy
Number of subjects: 301
Study 17466110 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 301
Study 15154923 — intervention group
Group type: EXPERIMENTAL
Intervention: Cacao bean husk extract (CBH) rinsing for 4 days, before and after meals and before sleeping.
Number of subjects: 49
Study 15154923 — intervention group
Group type: COMPARATOR
Intervention: 1% ethanol rinsing (control group).
Number of subjects: 49
Study 11529210 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning for six or more hours daily for 10 days
Number of subjects: 304
Study 11529210 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment in the supine position
Number of subjects: 304
Study 11529210 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 304
Study 9096189 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with a macrolide antibiotic (clarithromycin or azithromycin)
Number of subjects: 46
Study 8329260 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg/kg body weight
Number of subjects: 50
Study 8329260 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine 2 mg/kg body weight
Number of subjects: 50
Study 3010782 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir therapy
Number of subjects: 107
Study 30509638 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein meal with phosphorus (500 mg)
Number of subjects: 12
Study 30509638 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein meal with phosphorus (500 mg)
Number of subjects: 12
Study 30509638 — intervention group
Group type: COMPARATOR
Intervention: Normal protein meal without phosphorus
Number of subjects: 12
Study 30509638 — intervention group
Group type: COMPARATOR
Intervention: High protein meal without phosphorus
Number of subjects: 12
Study 27973411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI SSB (isomaltulose)
Number of subjects: 13
Study 27973411 — intervention group
Group type: COMPARATOR
Intervention: High-GI SSB (maltodextrin-sucrose)
Number of subjects: 13
Study 24713309 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial weekly transabdominal amnioinfusion (AI)
Number of subjects: 56
Study 24713309 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (Exp)
Number of subjects: 56
Study 24713309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AI and Exp
Number of subjects: 56
Study 24066639 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and relaxation practices (treated group)
Number of subjects: 110
Study 24066639 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group (control)
Number of subjects: 110
Study 21143403 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release paracetamol (PEx) 80 mg/kg
Number of subjects: 9
Study 21143403 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release paracetamol (APAP-IR) 80 mg/kg
Number of subjects: 9
Study 17664049 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 14
Study 17664049 — intervention group
Group type: COMPARATOR
Intervention: No Dexamethasone
Number of subjects: 14
Study 11872547 — intervention group
Group type: EXPERIMENTAL
Intervention: One stop clinic
Number of subjects: 670
Study 11872547 — intervention group
Group type: COMPARATOR
Intervention: Dedicated breast clinic
Number of subjects: 670
Study 9833950 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetyl-L-cysteine (1,200 mg/day)
Number of subjects: 15
Study 9833950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 7867316 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 58
Study 7867316 — intervention group
Group type: COMPARATOR
Intervention: Manic patients
Number of subjects: 58
Study 2518872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid (one tablet q.d.s. for 1.5 days)
Number of subjects: 20
Study 2518872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablet q.d.s. for 1.5 days)
Number of subjects: 20
Study 1053551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (SISD)
Number of subjects: 20
Study 31931647 — intervention group
Group type: EXPERIMENTAL
Intervention: methotrexate‐cytarabine‐thiotepa‐rituximab (MATRix)
Number of subjects: 0
Study 31931647 — intervention group
Group type: COMPARATOR
Intervention: methotrexate‐cytarabine‐rituximab
Number of subjects: 0
Study 31931647 — intervention group
Group type: COMPARATOR
Intervention: methotrexate‐cytarabine
Number of subjects: 0
Study 29960290 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduqing granules
Number of subjects: 72
Study 29960290 — intervention group
Group type: COMPARATOR
Intervention: Lianhuaqingwen capsules
Number of subjects: 72
Study 25936840 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 69
Study 25936840 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 69
Study 23524197 — intervention group
Group type: EXPERIMENTAL
Intervention: Primes related to task difficulty (high difficulty words)
Number of subjects: 0
Study 23524197 — intervention group
Group type: EXPERIMENTAL
Intervention: Primes related to personal significance (people's first names)
Number of subjects: 0
Study 21056640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot extract (BPF), given orally for 30 days
Number of subjects: 237
Study 19054529 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 162
Study 19054529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 16894335 — intervention group
Group type: EXPERIMENTAL
Intervention: ERr 731 (one enteric-coated tablet daily for 12 weeks)
Number of subjects: 109
Study 16894335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 15127021 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled slicing of the deciduous second molar between the ages of 8 and 9 years
Number of subjects: 0
Study 15127021 — intervention group
Group type: COMPARATOR
Intervention: Controlled slicing in 10‐ to 11‐year‐olds
Number of subjects: 0
Study 15127021 — intervention group
Group type: COMPARATOR
Intervention: Extraction alone
Number of subjects: 0
Study 11702035 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECARD program (health educational computer program for coronary risk prediction and multifactorial prevention)
Number of subjects: 11765
Study 11702035 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Risk Score (new coronary risk score for myocardial infarction)
Number of subjects: 11765
Study 9143783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glibenclamide
Number of subjects: 8
Study 9143783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8190435 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation with intact chorioamnion
Number of subjects: 118
Study 8190435 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin augmentation with amniotomy and internal monitoring
Number of subjects: 118
Study 3597738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-migration method in Earle's medium containing highly purified hyaluronic acid (Hya)
Number of subjects: 211
Study 3597738 — intervention group
Group type: COMPARATOR
Intervention: Traditional centrifugation method
Number of subjects: 211
Study 3597738 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-migration method in medium containing Hya
Number of subjects: 211
Study 3597738 — intervention group
Group type: COMPARATOR
Intervention: Media without Hya in self-migration method
Number of subjects: 211
Study 31039778 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 49
Study 31039778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 28094194 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1 (7.5 mg/kg every 2 weeks for 8 weeks)
Number of subjects: 333
Study 28094194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 28094194 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1
Number of subjects: 333